Skip to content

To compare the efficacy and safety of 730nm and 1064nm picosecond laser in the treatment of naevus fuscocyanozygomaticus

To compare the efficacy and safety of 730nm and 1064nm picosecond laser in the treatment of naevus fuscocyanozygomaticus

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065723
Enrollment
Unknown
Registered
2022-11-14
Start date
2022-11-14
Completion date
Unknown
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acquired bilateral nevus of Ota-like macules

Interventions

Group 1:730nm picosecond laser
Group 2:1064nm picosecond laser

Sponsors

Plastic Surgery Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily participate in this study, sign informed consent, agree to receive laser therapy and complete follow-up observation. 3. Aged between 18 and 65 years. 3. The diagnosis was acquired bilateral nevus of Ota-like macules.

Exclusion criteria

Exclusion criteria: 1. Locally used retinoic acid preparations, chemical stripping, bleach or other whitening products within the past 1 month; 2. Systematic use of retinoids and tranexamic acid within the past 6 months; 3. Received cryotherapy or treatment with various laser devices within the last 6 months; 4. People who have recently taken photosensitive drugs or have photosensitive diseases; 5. Locally combined with other pigmentary diseases; 6. Serious diseases such as important organic lesions; 7. Pregnant or lactating people; 8. Have high expectations of treatment outcomes; 9. Scarring prone.

Design outcomes

Primary

MeasureTime frame
Improvement degree of skin lesions;Pain visual analog scale score;

Countries

China

Contacts

Public ContactWangBaoxi

Plastic Surgery Hospital, Chinese Academy of Medical Sciences

wangbaoxi@psh.pumc.edu.cn+86 188 1308 1783

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026